Complementation of factor xi deficeincy by factor v mutants
AssigneeCrucell Holland B.V.
InventorsIngrid Van Den Nieuwenhof, Josephus C. M. Meijers, Christopher A. Yallop
Life of this patent
Estimating the term…
Abstract
Described are methods for preventing and/or treating bleeding in a subject with Factor XI deficiency, such as hemophilia C, which methods comprise administering to the subject APC-resistant Factor V.
Claims14
A method for preventing or treating bleeding in a patient with a Factor XI-deficiency, the method comprising administering to the patient APC-resistant Factor V.
A method for reducing or preventing the possibility of generating inhibitors to Factor XI in a hemophilia C patient, the method comprising administering APC-resistant Factor V to the patient.
A method of treating a subject suffering from a Factor XI-deficiency, the method comprising:
- administering to the subject recombinantly produced APC-resistant Factor V to obtain a plasma concentration thereof of between 0.1 and 5 Units/ml in the subject's plasma,
- wherein the APC-resistant Factor V has a mutation of Arg306, Arg506 or both Arg 306 and Arg506 as compared to the wild type Factor V sequence, and wherein the APC-resistant Factor V is free from other clotting factors.
Dependencies are inferred from the claim text.